Two leading biotechnology companies collaborate to gain further understanding of Parkinson’s disease

This week 23andMe (a genetic testing company) and Genentech (medical research company of the Roche Group) agreed a collaboration to undertake whole genome sequencing for 3,000 patients with Parkinson’s disease. The genetic information will be collected by 23andMe and used by Genentech to identify new therapeutic targets for treating Parkinson’s disease.



from The Medical News http://ift.tt/1xZ7La6